Aqueous drug
AssigneeKyorin Pharmaceutical Co., Ltd.
InventorsTakahiro Goto, Hitoshi Kozuka, Mizuho Shibata, Wataru Minagawa, Norihiro Kanayama, Chifuyu Toriumi
Life of this patent
Estimating the term…
Abstract
An aqueous drug that contains the compound represented by formula (1) or a salt thereof and in which the precipitation and the chemical dissolution of the compound of formula (1) or of a salt thereof is inhibited. An aqueous drug containing: the compound represented by formula (1) or a salt thereof; and a magnesium compound. The aqueous drug has a pH of 5.8-6.9. The concentration of the compound represented by formula (1) is 3 mg/mL or more.
Claims10
An aqueous liquid formulation comprising
- 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, and a magnesium compound, wherein
- the aqueous liquid formulation has a pH of 5.8 or more and 6.9 or less, and
- 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid is contained in a concentration of 3 mg/mL or more.
A method for inhibiting decomposition of a compound represented by general formula (1):
- (wherein R1 represents an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more substituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group, and a hydroxyl group, R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, or an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more substituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group and a hydroxyl group, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and X represents a halogen atom, or a salt thereof,
- comprising adding, to an aqueous liquid formulation that contains the compound represented by the general formula (1) or a salt thereof, a magnesium compound of which a molar ratio relative to the compound represented by the general formula (1) or a salt thereof is 0.45 or more and 1.5 or less, and making the concentration of the compound represented by the general formula (1) in the aqueous liquid formulation 3 mg/mL or more.
Dependencies are inferred from the claim text.